Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD
Aclarion, Inc. announces the availability of Nociscan, their diagnostic solution for chronic low back pain, at the Barrow Neurological Institute in Phoenix, AZ. Dr. Juan Uribe, a renowned neurosurgeon, is now the 3rd key opinion leader with access to the diagnostic center. Nociscan aims to help physicians identify the location of chronic low back pain noninvasively through chemical biomarkers and proprietary algorithms. The activation of the Phoenix market is expected to support scan volume growth in 2024.
The introduction of Aclarion's Nociscan to the greater Phoenix market, especially through an institution like Barrow Neurological Institute, represents a significant advancement in the noninvasive diagnosis and treatment of chronic low back pain (cLBP). The platform's ability to objectively quantify chemical biomarkers associated with disc pain and integrate this data into proprietary algorithms is a leap forward in precision medicine. This technology could potentially reduce the trial-and-error approach in treating cLBP, leading to more tailored and effective treatment plans, minimizing the risk of opioid addiction associated with this condition.
Furthermore, the economic implications of such a diagnostic tool are considerable. Given that cLBP is the most expensive diagnosis in the U.S., improvements in diagnosis and treatment could lead to substantial cost savings for the healthcare system. The reduction in unnecessary procedures, hospital stays and medication could also alleviate the financial burden on patients and insurers. However, the long-term success of Nociscan will depend on its integration into clinical practice and its acceptance by the wider medical community.
Aclarion's recent announcement of completing the 1,000th commercial Nociscan exam and the expansion into the Phoenix market with the support of key opinion leaders (KOLs) like Dr. Uribe signals a strategic growth phase for the company. This milestone could serve as a catalyst for increased scan volume and adoption rates, which are critical for the company's revenue growth. The involvement of KOLs is often a pivotal factor in the adoption of new medical technologies, as they can influence peers and contribute to wider industry acceptance.
Investors should monitor Aclarion's performance in this initial rollout phase to gauge the market's response to Nociscan. The technology's impact on Aclarion's financials will be more evident as the company expands its reach and increases the number of scans performed. The potential for Aclarion to capture a significant share of the cLBP diagnostic market is notable, but it will require careful analysis of the company's ability to scale and the healthcare industry's readiness to adopt such innovations.
The announcement by Aclarion and its implications for the stock market should be closely watched by investors. The availability of Nociscan at a respected institution like Barrow Neurological Institute, combined with the endorsement of a high-profile neurosurgeon, could enhance Aclarion's market credibility and drive investor confidence. The company's stock (Nasdaq: ACON, ACONW) may respond positively to this news, especially if Aclarion can demonstrate a clear path to profitability through increased adoption of Nociscan.
It is essential to evaluate Aclarion's financials, including its revenue growth, cost of scaling the technology and the potential market size for Nociscan. Investors should consider the company's capacity to leverage this technology to secure a competitive advantage and its ability to navigate the regulatory landscape, which can significantly impact the speed and extent of market penetration. Additionally, the role of Nociscan in reducing healthcare costs could make it an attractive proposition for insurance companies, potentially leading to partnerships and broader coverage for the scans.
01/22/2024 - 08:00 AM
Dr. Uribe is Chief of the Division of Spinal Disorders, Volker K. H. Sonntag Chair of Spine Research, and Vice Chairman of Neurosurgery at Barrow Neurological Institute
Dr. Uribe Becomes Aclarion’s 3rd KOL With Access to a Diagnostic Center Authorized to Perform Nociscans
BROOMFIELD, CO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Nociscan is now available in the greater Phoenix, AZ market at the Barrow Neurological Institute with Dr. Juan Uribe and other area physicians treating chronic low back pain.
Dr. Uribe's practice emphasizes a comprehensive approach to treating the spine and applying minimally invasive spine surgery to complex degenerative disease. “I have dedicated my life to alleviating the pain and suffering associated with spinal disorders. Low back pain is an extremely debilitating condition that lacks a noninvasive tool helping me identify the location of a patient's pain. I am pleased Nociscan is now available in the greater Phoenix market, which will help us continue to advance more accurate diagnosis and treatments for low back pain,” said Dr. Uribe.
Chronic low back pain (cLBP) is a leading cause of opioid addiction in the U.S. and the single most expensive diagnosis in the United States. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to highlight if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.
“Dr. Uribe is a renowned neurosurgeon at one of the world’s leading neurological institutes, Barrow,” said Ryan Bond, Chief Strategy Officer of Aclarion. “Throughout Dr. Uribe’s career he has rejected norms and advanced the treatment of chronic low back pain through research, education and adopting innovation. We are pleased that he and the medical community in Phoenix will now have access to Nociscan.”
Aclarion recently announced the completion of the 1,000th commercial Nociscan exam and pointed to additional KOLs gaining access to MRIs as a key catalyst for supporting scan volume growth in 2024. Activation of the Phoenix market represents the first such key catalyst of 2024.
For information about Nociscan use in Phoenix, please contact Aclarion at info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Prospectus dated April 21, 2022, as filed with the Securities and Exchange Commission on April 25, 2022 under Rule 424(b)(4), as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts: ksmith@pcgadvisory.com
Media Contacts: jodi@sprigconsulting.com
What is the name of the healthcare technology company in the press release?
The healthcare technology company mentioned in the press release is Aclarion, Inc.
What is the ticker symbol for Aclarion, Inc.?
The ticker symbol for Aclarion, Inc. is ACON.
What is the purpose of Nociscan?
Nociscan is a diagnostic solution aimed at helping physicians identify the location of chronic low back pain noninvasively through chemical biomarkers and proprietary algorithms.
Who is Dr. Juan Uribe?
Dr. Juan Uribe is the Chief of the Division of Spinal Disorders, Volker K. H. Sonntag Chair of Spine Research, and Vice Chairman of Neurosurgery at Barrow Neurological Institute.
What is the significance of the activation of the Phoenix market for Aclarion, Inc.?
The activation of the Phoenix market represents a key catalyst for supporting scan volume growth in 2024 for Aclarion, Inc.
